Click to go to DrugInjuryLaw Home


Legal information and news about prescription drug side effects
NuvaRing Case Evaluation Ortho Evra Case Evaluation Fosamax Case Evaluation Avandia Case EvaluationKetek Case Evaluation Zelnorm Case Evaluation Meridia Case Evaluation Zocor Case Evaluation
Vytorin Case EvaluationZetia Case Evaluation Yasmin Case Evaluation Ocella Case EvaluationYAZ Case Evaluation Levaquin Case Evaluation Byetta Case Evaluation Gianvi Case Evaluation


Free Case Evaluation

2005 Dear Doctor Letter Issued In Canada for Cholesterol Drug Ezetrol/Zetia

No Corresponding Letter Sent To US Doctors As Of 2007

On February 1, 2005 Health Canada posted a Dear Doctor letter warning about Zetia (ezetimibe) -- Called Ezetrol in Canada -- on its site from Merck Frosst / Schering Pharmaceuticals. The letter was intended to draw attention to some serious side effects associated with Zetia, including:

The Warnings, Precautions, and Adverse Events sections are being updated to reflect the occurrence of the following adverse events in patients taking EzetrolŪ (ezetimibe) alone or in combination with a statin:
  • myalgia;
  • rhabdomyolysis;
  • hepatitis;
  • acute pancreatitis;
  • thrombocytopenia; and
  • suspected interaction between EzetrolŪ (ezetimibe) and warfarin

Additionally, the Canadian Dear Doctor letter warned of the possibility of liver injuries associated with the use of Zetia and a statin drug (such as Zocor, Lipitor, Crestor, Lescol, Mevacor, or Pravachol):

Adverse hepatic events:

Elevations of liver transaminases and cases of hepatitis have been reported in patients treated with [Zetia]. Liver function monitoring is recommended when therapy with [Zetia] is initiated in patients treated or about to begin treatment with a statin.

Health care professionals should be aware that the use of [Zetia] in combination with a statin is contraindicated in patients with active liver disease or unexplained persistent elevations of liver transaminases.

Subsequent to the 2005 Dear Doctor letter about Zetia was sent by the Merck and Schering group in Canada there have been some case reports of serious liver injury in patients using Zetia and statins -- but for the most part Zetia-induced liver injury had been off-the-radar for most drug safety observers.

In the U.S., however, the drug companies responsible for Zetia, Merck and Schering-Plough, chose not to send any corresponding Dear Doctor letter to American health care professionals, nor did the FDA mandate that they do so. The risks associated with Zetia have only recently been brought to public attention in a New York Times article about unpublished Zetia studies.

Read more about Zetia on our Zetia and Vytorin Information Page >>


  • US FDA advises that you should not stop taking any prescription medication before talking to your doctor.
  • Reports of serious drug side effects should be made to the US FDA MedWatch program.
  • The prescription drug names are registered trademarks of the respective drug companies.
  • DrugInjuryLaw.com is not affiliated with any of the drug companies, nor US FDA.
Law Offices of Thomas J. Lamb, P.A.
Lumina Station Suite 225
1908 Eastwood Road
Wilmington, NC 28403
Tel: (910) 256-2971   Fax: (910) 256-2972
Toll Free: (800) 426-9535
email: ThomasJLamb@DrugInjuryLaw.com

Disclaimer